JP2019535306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535306A5 JP2019535306A5 JP2019542804A JP2019542804A JP2019535306A5 JP 2019535306 A5 JP2019535306 A5 JP 2019535306A5 JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019542804 A JP2019542804 A JP 2019542804A JP 2019535306 A5 JP2019535306 A5 JP 2019535306A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- monoclonal antibody
- binding fragment
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 102000001708 Protein Isoforms Human genes 0.000 claims 3
- 108010029485 Protein Isoforms Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306392.8 | 2016-10-25 | ||
| EP16306392 | 2016-10-25 | ||
| PCT/EP2017/077261 WO2018077926A1 (en) | 2016-10-25 | 2017-10-25 | Monoclonal antibodies binding to the cd160 transmembrane isoform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535306A JP2019535306A (ja) | 2019-12-12 |
| JP2019535306A5 true JP2019535306A5 (enExample) | 2020-12-03 |
Family
ID=57570549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542804A Pending JP2019535306A (ja) | 2016-10-25 | 2017-10-25 | Ｃｄ１６０膜貫通型アイソフォームと結合するモノクローナル抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11186635B2 (enExample) |
| EP (1) | EP3532502A1 (enExample) |
| JP (1) | JP2019535306A (enExample) |
| KR (1) | KR20190084264A (enExample) |
| CN (1) | CN110121508A (enExample) |
| AU (1) | AU2017351764A1 (enExample) |
| BR (1) | BR112019008345A8 (enExample) |
| CA (1) | CA3080270A1 (enExample) |
| WO (1) | WO2018077926A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123338A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP3812008A1 (en) * | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| GB202103706D0 (en) * | 2021-03-17 | 2021-04-28 | Ucl Business Ltd | CD160 binding domain |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| CN119137151A (zh) * | 2022-03-09 | 2024-12-13 | 阿德莱恩生物技术公司 | 抗cd160跨膜同种型抗体 |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5094941A (en) * | 1987-12-31 | 1992-03-10 | Zymogenetics, Inc. | Monoclonal antibodies to PDGF |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2412701A1 (en) | 2000-06-28 | 2002-01-03 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| ES2307832T3 (es) | 2001-12-03 | 2008-12-01 | Amgen Fremont Inc. | Clasificacion de anticuerpos basada en las caracteristicas de union. |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| PL2489364T3 (pl) | 2003-11-06 | 2015-06-30 | Seattle Genetics Inc | Związki monometylowaliny zdolne do sprzęgania do przeciwciał |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1626059A1 (en) | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| ES2715776T3 (es) | 2004-11-12 | 2019-06-06 | Seattle Genetics Inc | Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| ES2649550T3 (es) | 2005-07-18 | 2018-01-12 | Seattle Genetics, Inc. | Conjugados del enlazador fármaco de beta-glucurónido |
| EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
| US8247537B2 (en) * | 2006-11-15 | 2012-08-21 | Medarex, Inc. | Human monoclonal antibodies to BTLA and methods of use |
| EP2006299A1 (en) | 2007-06-18 | 2008-12-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Identification of new isoforms of the MHC-class I specific receptor CD160 and uses thereof |
| EP2210903A1 (en) * | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| US20130045871A1 (en) * | 2010-03-18 | 2013-02-21 | Cornell University | Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates |
| EP2575881B1 (en) * | 2010-05-28 | 2016-09-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
| CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013072714A1 (en) * | 2011-11-15 | 2013-05-23 | Centre National De La Recherche Scientifique (Cnrs) | Antibodies for molecular imaging of vulnerable plaques in atherosclerosis |
| JP2018508191A (ja) | 2015-01-16 | 2018-03-29 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | オレキシン受容体１型に対するヒトモノクローナル抗体 |
-
2017
- 2017-10-25 CN CN201780080063.4A patent/CN110121508A/zh active Pending
- 2017-10-25 WO PCT/EP2017/077261 patent/WO2018077926A1/en not_active Ceased
- 2017-10-25 KR KR1020197014634A patent/KR20190084264A/ko not_active Ceased
- 2017-10-25 CA CA3080270A patent/CA3080270A1/en not_active Abandoned
- 2017-10-25 US US16/343,889 patent/US11186635B2/en active Active
- 2017-10-25 BR BR112019008345A patent/BR112019008345A8/pt not_active Application Discontinuation
- 2017-10-25 AU AU2017351764A patent/AU2017351764A1/en not_active Abandoned
- 2017-10-25 EP EP17797084.5A patent/EP3532502A1/en active Pending
- 2017-10-25 JP JP2019542804A patent/JP2019535306A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535306A5 (enExample) | ||
| JP7345578B2 (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| TWI853077B (zh) | 新型抗ｃｄ３９抗體 | |
| CN109535257B (zh) | 新型双特异性cd3/cd19多肽复合物 | |
| JP2017504577A5 (enExample) | ||
| JP2016527314A5 (enExample) | ||
| JP2018519296A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| JP2018508214A5 (enExample) | ||
| CA3044684A1 (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| JP2016531100A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| CN120554507A (zh) | 拮抗剂抗cd7抗体 | |
| JP2018520667A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2018524326A5 (enExample) | ||
| JP2015533853A5 (enExample) | ||
| JP2014523408A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| CN114761429B (zh) | 新型抗cd3/抗egfr双特异性抗体及其用途 | |
| CN115093481A (zh) | 新型双特异性cd3/cd20多肽复合物 | |
| JP2017537082A5 (enExample) | ||
| CN113164520A (zh) | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |